Get the Stockscreener App
14.28
20.00%
-3.57
Novocure Ltd stock is traded at $14.28, with a volume of 4.63M.
It is down -20.00% in the last 24 hours and down -18.21% over the past month.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
See More
Previous Close:
$17.85
Open:
$15.03
24h Volume:
4.63M
Relative Volume:
3.02
Market Cap:
$1.65B
Revenue:
$674.41M
Net Income/Loss:
$-173.05M
P/E Ratio:
-9.3072
EPS:
-1.5343
Net Cash Flow:
$-48.07M
1W Performance:
-19.37%
1M Performance:
-18.21%
6M Performance:
+13.69%
1Y Performance:
-15.00%
1-Day Range:
$13.88
$15.10
1-Week Range:
$13.88
$18.35
52-Week Range:
$9.82
$18.92
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
14.28 | 1.65B | 674.41M | -173.05M | -48.07M | -1.5343 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
NovoCure (NVCR) Is Down 19.7% After TRIDENT Misses Survival Endpoint In Earlier TTFields Use - simplywall.st
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? - Yahoo Finance
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - Barchart.com
Novocure (NVCR) Experiences Significant Decline in Stock Price - GuruFocus
NovoCure (NVCR) Stock Could Be 31.5% Undervalued After TRIDENT Trial Result - simplywall.st
NVCR Reiterated by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Novocure’s Optune Gio fails to show benefit at earlier stage - Yahoo Finance
Novocure TRIDENT trial misses primary endpoint - grafa.com
Novocure (NVCR) Reports TRIDENT Trial Results for Glioblastoma T - GuruFocus
Novocure Announces Topline Phase 3 TRIDENT Trial Data for TTFields Therapy in Newly Diagnosed Glioblastoma Patients – Minichart - Minichart
Novocure (NVCR) Faces 20% Drop After Phase 3 Trial Setback - GuruFocus
Novocure (NVCR) Sees Significant Decline in Stock Price - GuruFocus
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks - Benzinga
Novocure Shares Slide After Phase 3 Glioblastoma Study Falls Short of Survival Goal - Yahoo Finance
Novocure device fails to improve brain cancer patients’ survival in phase 3 test - Fierce Biotech
Why is Novocure stock plummeting today? By Investing.com - Investing.com Australia
FreeCast surges premarket; Accenture, Novocure slide - Investing.com
FreeCast surges premarket; Accenture, Novocure slide By Investing.com - Investing.com India
Novocure’s glioblastoma trial fails primary endpoint - Investing.com
Novocure’s glioblastoma trial fails primary endpoint By Investing.com - Investing.com Canada
Novocure stock tumbles after trial misses primary endpoint By Investing.com - Investing.com South Africa
Novocure (NASDAQ: NVCR) Phase 3 TRIDENT glioblastoma study misses survival endpoint - Stock Titan
Novocure's glioblastoma trial shows survival data, but no primary win - Stock Titan
Novocure Ltd (NVCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Novocure Ltd (NVCR) Institutional Confidence - TradingKey
Novocure Ltd (NVCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Novocure Ltd (NVCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Novocure Ltd (NVCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Novocure Ltd (NVCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Novocure Ltd (NVCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Novocure Ltd (NVCR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Novocure Ltd (NVCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
NovoCure (NVCR) Appoints Frank Leonard To Its Board After Shareholder Vote - simplywall.st
NovoCure Ltd stock (JE00B6T5S470): Focus on Tumor Treating Fields technology as investors weigh rece - AD HOC NEWS
Frank Leonard’s Board Appointment and Insider Selling Might Change The Case For Investing In NovoCure (NVCR) - Yahoo Finance
Have Insiders Sold NovoCure Shares Recently? - simplywall.st
NovoCure Limited Adopts Amended and Restated 2024 Omnibus Incentive Plan and Reports 2026 Annual Meeting Results - Minichart
Novocure Insider Sold Shares Worth $614,635, According to a Recent SEC Filing - marketscreener.com
NovoCure Limited Elects Frank Leonard as Director, Effective June 3, 2026 - marketscreener.com
NovoCure (NASDAQ: NVCR) investors OK directors and tight 2024 incentive plan vote - Stock Titan
NovoCure (NVCR) CEO sells 34,273 shares in tax-related transaction - Stock Titan
NovoCure (NASDAQ: NVCR) director granted RSUs and options in new equity awards - Stock Titan
NovoCure (NASDAQ: NVCR) director granted RSUs and options in 2026 award - Stock Titan
NovoCure (NVCR) director receives new share and stock option awards - Stock Titan
NovoCure (NVCR) grants RSUs and stock options to director Scannell - Stock Titan
NovoCure (NASDAQ: NVCR) director granted RSUs and 16,999 stock options - Stock Titan
[Form 4] NovoCure Ltd Insider Trading Activity - Stock Titan
NovoCure (NASDAQ: NVCR) awards director new RSUs and stock options - Stock Titan
NovoCure (NASDAQ: NVCR) grants RSUs and stock options to director Vernon W. Anthony - Stock Titan
NovoCure Ltd stock (JE00B6T5S470): shares jump after double-digit move puts focus on valuation - AD HOC NEWS
Is It Too Late to Buy NovoCure Ltd (NVCR) After 11.4% Rally? GF Value Says Undervalued - GuruFocus
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):